Inventor · disambiguated record
Sami Karaborni
Also filed as: KARABORNI SAMI
30 granted patents·22 pending applications·35 citations·filing 2003–2025
95Inventor score
Files withXENOPORT INC15XWPHARMA LTD14ARBOR PHARMACEUTICALS LLC11RAPT THERAPEUTICS INC2SPRUCE BIOSCIENCES INC2
Top patents by PatentIndex Score
52 records- 0195US11395801B2Modified release compositions of a gamma-hydroxybutyric acid derivativeXWPHARMA LTD·Filed 2021·Granted Jul 26, 2022·9 cites·18 claims
- 0291US11938111B2Pharmaceutical compositions of dimethyl fumarateARBOR PHARMACEUTICALS LLC·Filed 2021·Granted Mar 26, 2024·1 cites·7 claims
- 0390US10576055B2Pharmaceutical compositions of dimethyl fumarateARBOR PHARMACEUTICALS LLC·Filed 2018·Granted Mar 3, 2020·2 cites·16 claims
- 0489US11304906B2Controlled release granulations of water-soluble active pharmaceutical ingredientsXWPHARMA LTD·Filed 2021·Granted Apr 19, 2022·2 cites·16 claims
- 0589US11229621B2Pharmaceutical compositions of dimethyl fumarateARBOR PHARMACEUTICALS LLC·Filed 2020·Granted Jan 25, 2022·2 cites·7 claims
- 0688US12440468B2Pharmaceutical compositions of dimethyl fumarateARBOR PHARMACEUTICALS LLC·Filed 2024·Granted Oct 14, 2025·0 cites·12 claims
- 0788US11357734B2Pharmaceutical granulations of water-soluble active pharmaceutical ingredientsXWPHARMA LTD·Filed 2021·Granted Jun 14, 2022·1 cites·18 claims
- 0888US10179118B2Pharmaceutical compositions of dimethyl fumarateXENOPORT INC·Filed 2014·Granted Jan 15, 2019·3 cites·13 claims
- 0985US12396956B2Modified release compositions of a gamma-hydroxybutyric acid derivativeXWPHARMA LTD·Filed 2024·Granted Aug 26, 2025·0 cites·19 claims
- 1085US10716760B2Oral dosage forms of methyl hydrogen fumarate and prodrugs thereofXENOPORT INC·Filed 2016·Granted Jul 21, 2020·2 cites·18 claims
- 1183US9421182B2Cocrystals of dimethyl fumarateXENOPORT INC·Filed 2014·Granted Aug 23, 2016·2 cites·10 claims
- 1283US8399513B2Levodopa prodrug mesylate hydrateKARABORNI SAMI·Filed 2009·Granted Mar 19, 2013·4 cites·24 claims
- 1382US10940117B2Oral dosage forms of methyl hydrogen fumarate and prodrugs thereofARBOR PHARMACEUTICALS LLC·Filed 2020·Granted Mar 9, 2021·1 cites·12 claims
- 1482US10865198B2Solid forms of cerdulatinibPORTOLA PHARM INC·Filed 2019·Granted Dec 15, 2020·3 cites·40 claims
- 1582US2025352481A1Modified release compositions of a gamma-hydroxybutyric acid derivativeXWPHARMA LTD·Filed 2025·Application pending·0 cites
- 1680US2025352496A1Pharmaceutical compositions and oral dosage forms of ketamine derivativesXWPHARMA LTD·Filed 2025·Application pending·0 cites
- 1779US12396966B2Pharmaceutical compositions and oral dosage forms of ketamine derivativesXWPHARMA LTD·Filed 2023·Granted Aug 26, 2025·0 cites·23 claims
- 1879US2024024249A1Oral dosage forms having a high loading of a methyl hydrogen fumarate prodrugARBOR PHARMACEUTICALS LLC·Filed 2023·Application pending·0 cites
- 1978US11925710B2Modified release compositions of a GAMMA-hydroxybutyric acid derivativeXWPHARMA LTD·Filed 2022·Granted Mar 12, 2024·0 cites·20 claims
- 2078US10945984B2Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effectsARBOR PHARMACEUTICALS LLC·Filed 2013·Granted Mar 16, 2021·1 cites·12 claims
- 2177US11690811B2Pharmaceutical compositions and oral dosage forms of ketamine derivativesXWPHARMA LTD·Filed 2022·Granted Jul 4, 2023·0 cites·8 claims
- 2276US9999672B2Pharmaceutical compositions of fumaric acid estersXENOPORT INC·Filed 2015·Granted Jun 19, 2018·1 cites·25 claims
- 2376US2025041258A1Pharmaceutical compositions of a gamma-hydroxybutyric acid derivativeXWPHARMA LTD·Filed 2024·Application pending·0 cites
- 2476US2025041425A1Excipient granulationsXWPHARMA LTD·Filed 2024·Application pending·0 cites
- 2573US12337066B2Controlled release granulations of water-soluble active pharmaceutical ingredientsXWPHARMA LTD·Filed 2022·Granted Jun 24, 2025·0 cites·21 claims
- 2673US9416096B2Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and useXENOPORT INC·Filed 2014·Granted Aug 16, 2016·1 cites·19 claims
- 2773US2024317768A1Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereofRAPT THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2872US2025262157A1Controlled release granulations of water-soluble active pharmaceutical ingredientsXWPHARMA LTD·Filed 2025·Application pending·0 cites
- 2971US2024197661A1Oral dosage forms of methyl hydrogen fumarate and prodrugs thereofARBOR PHARMACEUTICALS LLC·Filed 2023·Application pending·0 cites
- 3070US11135296B2Pharmaceutical compositions of fumaric acid estersARBOR PHARMACEUTICALS LLC·Filed 2018·Granted Oct 5, 2021·0 cites·7 claims
- 3170US2021145755A1Oral dosage forms of methyl hydrogen fumarate and prodrugs thereofARBOR PHARMACEUTICALS LLC·Filed 2021·Application pending·0 cites
- 3268US2022323366A1Pharmaceutical granulations of water-soluble active pharmaceutical ingredientsXWPHARMA LTD·Filed 2022·Application pending·0 cites
- 3366US12006318B2Crystalline forms of C-C chemokine receptor type 4 antagonist and uses thereofRAPT THERAPEUTICS INC·Filed 2020·Granted Jun 11, 2024·0 cites·46 claims
- 3462US8722733B2Levodopa prodrug mesylate hydrateXENOPORT INC·Filed 2013·Granted May 13, 2014·0 cites·19 claims
- 3561US11713309B2Solid forms of CerdulatinibALEXION PHARMA INC·Filed 2020·Granted Aug 1, 2023·0 cites·32 claims
- 3661US9895336B2Crystalline forms of (N, N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and useXENOPORT INC·Filed 2017·Granted Feb 20, 2018·0 cites·11 claims
- 3761US9795581B2Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and useXENOPORT INC·Filed 2017·Granted Oct 24, 2017·0 cites·14 claims
- 3861US9597292B2Oral dosage forms of methyl hydrogen fumarate and prodrugs thereofXENOPORT INC·Filed 2013·Granted Mar 21, 2017·0 cites·4 claims
- 3961US2020000758A1Oral Dosage Forms Of Methyl Hydrogen Fumarate And Prodrugs ThereofXENOPORT INC·Filed 2019·Application pending·0 cites
- 4061US2021228525A1Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side EffectsARBOR PHARMACEUTICALS LLC·Filed 2021·Application pending·0 cites
- 4160US9682057B2Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and useXENOPORT INC·Filed 2016·Granted Jun 20, 2017·0 cites·11 claims
- 4259US11008321B2Crystalline form of an avibactam derivativeARIXA PHARMACEUTICALS INC·Filed 2020·Granted May 18, 2021·0 cites·12 claims
- 4355US2015079180A1Nanoparticle compositions of dimethyl fumarateXENOPORT INC·Filed 2014·Application pending·0 cites
- 4454US2023365564A1Cocrystals of an adenosine a2b receptor antagonistTEON THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4551US2024217961A1(S)-Mepazine Salt Forms, Process of Preparing, and Formulations ThereofMONOPTEROS THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4648US2020255436A1Corticotropin releasing factor receptor antagonistsSPRUCE BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 4747US2006030581A1Mannitol formulation for integrin receptor antagonistDEBUSI LAURA A·Filed 2003·Application pending·0 cites
- 4840US2017035714A1Oral Dosage forms having a High Loading of a Gabapentin ProdrugXENOPORT INC·Filed 2016·Application pending·0 cites
- 4940US2021137935A1Corticotropin releasing factor receptor antagonistsSPRUCE BIOSCIENCES INC·Filed 2018·Application pending·0 cites
- 5037US2010226981A1Oral dosage forms having a high loading of a gabapentin prodrugXENOPORT INC·Filed 2010·Application pending·0 cites
Showing the top 50 of 52 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →